Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura.
High-dose intravenous immunoglobulin (IVIG) is considered a safe and efficacious treatment for patients with a variety of hematological and non hematological diseases, including patients with idiopathic thrombocytopenic purpura (ITP) not responsive or with contraindications to corticosteroids and/or splenectomy. Side-effects are usually minor, but severe reactions have been rarely reported. We describe the case of a patient with ITP, without pre-existing renal disease, who developed a severe transitory acute renal failure following administration of IVIG, promptly reversed after hemodialysis.
Ruggeri
M
M
Centro Regionale per lo Studio delle Malattie Emorragiche e Trombotiche, Ospedale San Bortolo, Vicenza.
Castaman
G
G
De Nardi
G
G
Rodeghiero
F
F
D058186:Acute Kidney Injury / Q000209:etiology*; D000368:Aged; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy*
D016756:Immunoglobulins, Intravenous